Ceres Pharma has acquired CEUMED, a pharmaceutical and cosmetics group operating in six CEE and SEE countries, to enhance its product portfolio and expand into new markets.

Target Information

CEUMED is a pharmaceutical and cosmetics group that specializes in the production, marketing, and distribution of over-the-counter (OTC) and cosmetic products. The company operates across six countries in Central and Eastern Europe (CEE) and Southeast Europe (SEE). With a strong focus on expanding its product portfolio and market reach, CEUMED has established itself as a key player in the region’s health and beauty sector.

Recently, CEUMED has been acquired by Ceres Pharma, a Belgian-based company known for its rapid growth and strategic acquisitions. Founded by the former owners of Omega Pharma, Ceres Pharma has generated €130 million in revenue and has expanded its presence into seven countries, completing a total of twelve acquisitions between 2018 and 2023. This strategic acquisition positions Ceres Pharma to leverage CEUMED's capabilities and market access.

Industry Overview

The pharmaceutical and cosmetics industry in the CEE and SEE regions has shown resilience and growth potential, particularly in the OTC segment. Unlike Western Europe, where market gro

View Source

Similar Deals

Danone The Akkermansia Company (TAC)

2025

Buyout Biotechnology & Medical Research (NEC) Belgium
Materialise FEops

2024

Buyout Hospitals, Clinics & Primary Care Services Belgium
Whitestone Lambda-X Ophtalmics

2024

Buyout Glasses, Spectacles & Contact Lenses Belgium
CellCarta Biogazelle

2021

Buyout Bio Diagnostics & Testing Belgium
Bruker Corporation MOLECUBES NV

2021

Buyout Bio Medical Devices Belgium
IMV Technologies Veterinary Solutions

Buyout Veterinary Medical Equipment & Supplies Belgium

Ceres Pharma

invested in

CEUMED

in 2023

in a Buyout deal

Disclosed details

Revenue: $143M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert